Icatibant Amarox (Icatibant)

Icatibant works by selectively blocking the bradykinin B2 receptor on blood vessel walls. This inhibition prevents bradykinin‑induced vasodilation and increased vascular permeability, which are responsible for the rapid swelling seen in HAE attacks.

The dose of Icatibant Amarox is determined by the prescribing clinician based on the patient’s condition, weight, and clinical response. The medication is administered as a subcutaneous injection, and the exact regimen should follow the healthcare provider’s instructions.

Safety data for icatibant in pregnancy and lactation are limited. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and import documentation.

Icatibant is a selective bradykinin B2 receptor antagonist, whereas other HAE therapies such as C1‑esterase inhibitor concentrates replace a deficient protein, and newer monoclonal antibodies target upstream components of the kallikrein‑kinin system. Icatibant offers rapid subcutaneous administration and works directly at the receptor level.

Icatibant Amarox should be stored refrigerated at 2‑8 °C, protected from light, and must not be frozen or shaken. If temporary storage at room temperature is unavoidable, limit exposure to no more than 30 °C for a short period and return to refrigeration promptly.

Icatibant is given as a single subcutaneous injection into the abdomen, thigh, or upper arm. The injection is performed by a trained healthcare professional or, after proper instruction, by the patient or caregiver for self‑administration during an HAE attack.

The most serious risks include anaphylaxis, severe hypersensitivity reactions, and paradoxical angioedema that may affect the airway. Patients should be monitored closely after the first dose and instructed to seek immediate medical attention if they experience signs of a severe allergic reaction.

Icatibant is contraindicated in individuals with a known hypersensitivity to icatibant or any of its excipients. Caution is also advised for patients with severe renal or hepatic impairment, and it should be avoided in those who are pregnant or breastfeeding unless clearly indicated by a physician.